These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3671454)

  • 1. Release of plasminogen activator by molsidomine and its active metabolite SIN-1.
    Klöcking HP; Hoffmann A; Markwardt F
    Pharmazie; 1987 May; 42(5):354. PubMed ID: 3671454
    [No Abstract]   [Full Text] [Related]  

  • 2. [Release of plasminogen activator by SIN-1].
    Kloecking HP; Hoffmann A; Markwardt F
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):231-2. PubMed ID: 3104866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antithrombotic properties of the active metabolite of molsidomine, SIN-1].
    Grodzinska L; Basista M; Koenig E
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):233-4. PubMed ID: 3550644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the cardioprotective effect of nitroglycerin, molsidomine and SIN-1 in rats with cardiac hypoxia.
    Gaál J; Vértesi C; Knopf E; Körmöczy PS
    Acta Physiol Hung; 1990; 75 Suppl():117-8. PubMed ID: 2115223
    [No Abstract]   [Full Text] [Related]  

  • 5. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
    Wildgrube HJ; Ostrowski J; Chamberlain J; Gärtner W; Stockhausen H
    Arzneimittelforschung; 1986 Jul; 36(7):1129-33. PubMed ID: 3768083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of nitric oxide donors on the release of plasminogen activator inhibitor (PAI) from rabbit platelets in vitro.
    Korbut R; Marcinkiewicz E; Cieślik K; Gryglewski RJ
    J Physiol Pharmacol; 1995 Mar; 46(1):37-44. PubMed ID: 7599336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of molsidomine, an anti-anginal drug, on arachidonic acid metabolism in human platelets.
    Croset M; Lagarde M
    Biomed Biochim Acta; 1984; 43(8-9):S354-7. PubMed ID: 6440549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the effects of molsidomine and 3-morpholinosydnonimine on the redox status of rat erythrocytes and reticulocytes.
    Marković SD; Vukajlović MDj; Ognjanović BI; Stajn AS; Zikić RV; Saicić ZS; Radojicić RM; Jones DR; Spasić MB
    Cell Biochem Funct; 2007; 25(3):251-8. PubMed ID: 16397909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracavernous application of SIN-I in rabbit and man: functional and toxicological results.
    Meyer MF; Taher A; Krah H; Staubesand J; Becker AJ; Kircher M; Mayer B; Jonas U; Forssmann WG; Stief CG
    Ann Urol (Paris); 1993; 27(3):179-82. PubMed ID: 8352581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nitric oxide donor SIN-1 is a potent inhibitor of plasminogen activator inhibitor release from stimulated platelets.
    Drummer C; Lüdke S; Spannagl M; Schramm W; Gerzer R
    Thromb Res; 1991 Sep; 63(5):553-6. PubMed ID: 1755008
    [No Abstract]   [Full Text] [Related]  

  • 11. Determination of the active metabolite of molsidomine in human plasma by reversed-phase high-performance liquid chromatography.
    Dutot C; Moreau J; Cordonnier P; Spreux-Varoquaux O; Klein C; Ostrowski J; Advenier C; Gärtner W; Pays M
    J Chromatogr; 1990 Jun; 528(2):435-46. PubMed ID: 2384581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.
    Stoschus B; Fernandez I; Heller J; Neubrand M; Sauerbruch T
    Hepatogastroenterology; 1999; 46(26):933-7. PubMed ID: 10370642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of phenol ring polymers on the release of plasminogen activators].
    Klöcking HP; Klöcking R; Helbig B
    Farmakol Toksikol; 1984; 47(1):93-5. PubMed ID: 6538511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diameter changes of epicardial coronary arteries and coronary stenoses after intracoronary application of SIN 1, a molsidomine metabolite].
    Schulz W; Wendt T; Scherer D; Kober G
    Z Kardiol; 1983 Jul; 72(7):404-9. PubMed ID: 6613236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute release of plasminogen activator by ethyl alcohol in the isolated perfused pig ear.
    Klöcking HP; Hoffmann A; Sonntag G
    Pharmazie; 1990 May; 45(5):378-9. PubMed ID: 2395906
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
    Basista M; Grodzińska L; Swies J
    Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the direct NO-donor SIN-1 on the interaction between platelets and stainless steel stents under dynamic conditions.
    Jung F; Mrowietz C; Seyfert UT; Grewe R; Franke RP
    Clin Hemorheol Microcirc; 2003; 28(4):189-99. PubMed ID: 12897410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The heparin--tissue plasminogen activator complex and some of its properties].
    Shimonaeva EE; Shimonaev GS; Aleshina TS
    Biokhimiia; 1983 Oct; 48(10):1687-90. PubMed ID: 6685533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of sydnonimines derivatives on the antithrombogenic activity of endothelial cells in culture].
    Berenger FP; Cano JP; Rolland PH
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):241-3. PubMed ID: 3550646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Morpholinylsydnonimine inhibits glutamatergic transmission in rat rostral ventrolateral medulla via peroxynitrite formation and adenosine release.
    Huang CC; Chan SH; Hsu KS
    Mol Pharmacol; 2004 Sep; 66(3):492-501. PubMed ID: 15322240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.